CN112891237A - Phenethyl resorcinol slow-release oil agent for whitening and spot lightening - Google Patents
Phenethyl resorcinol slow-release oil agent for whitening and spot lightening Download PDFInfo
- Publication number
- CN112891237A CN112891237A CN202110298197.1A CN202110298197A CN112891237A CN 112891237 A CN112891237 A CN 112891237A CN 202110298197 A CN202110298197 A CN 202110298197A CN 112891237 A CN112891237 A CN 112891237A
- Authority
- CN
- China
- Prior art keywords
- resorcinol
- whitening
- skin
- spot
- lightening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VNXWANZMRATDQM-UHFFFAOYSA-N 2-(2-phenylethyl)benzene-1,3-diol Chemical compound OC1=CC=CC(O)=C1CCC1=CC=CC=C1 VNXWANZMRATDQM-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 230000002087 whitening effect Effects 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 16
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 13
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 239000011159 matrix material Substances 0.000 claims abstract description 9
- 235000019198 oils Nutrition 0.000 claims description 19
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 6
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 3
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 3
- 241000723343 Cichorium Species 0.000 claims description 3
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 3
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 3
- 229940039697 alkanna tinctoria root extract Drugs 0.000 claims description 3
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 3
- 229940036350 bisabolol Drugs 0.000 claims description 3
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 3
- 229960003720 enoxolone Drugs 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 2
- PQSXNIMHIHYFEE-UHFFFAOYSA-N 4-(1-phenylethyl)benzene-1,3-diol Chemical compound C=1C=C(O)C=C(O)C=1C(C)C1=CC=CC=C1 PQSXNIMHIHYFEE-UHFFFAOYSA-N 0.000 abstract description 29
- 210000003491 skin Anatomy 0.000 abstract description 29
- 229940106025 phenylethyl resorcinol Drugs 0.000 abstract description 28
- 210000002752 melanocyte Anatomy 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 9
- 102000003425 Tyrosinase Human genes 0.000 abstract description 8
- 108060008724 Tyrosinase Proteins 0.000 abstract description 8
- 102000004127 Cytokines Human genes 0.000 abstract description 6
- 108090000695 Cytokines Proteins 0.000 abstract description 6
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 206010015150 Erythema Diseases 0.000 abstract description 5
- 230000000638 stimulation Effects 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 201000004624 Dermatitis Diseases 0.000 abstract description 2
- 208000003251 Pruritus Diseases 0.000 abstract description 2
- 206010042674 Swelling Diseases 0.000 abstract description 2
- 238000005562 fading Methods 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a phenylethyl resorcinol slow-release oil agent for whitening and spot-lightening, which comprises caprylic capric triglyceride matrix, an anti-inflammatory composition and phenylethyl resorcinol. The anti-inflammatory composition can inhibit and antagonize the stimulation of various inflammatory factors and cytokines outside the melanocyte to the melanocyte at multiple targets, so that the whitening and spot-lightening efficiency of the product is higher, and the effect is better; meanwhile, the anti-inflammatory composition can improve skin inflammation, such as symptoms of redness, sensitivity, pruritus, redness and swelling, and the like, and achieve additional benefits; the caprylic/capric triglyceride matrix oil solution added with the phenethyl resorcinol has strong inhibition on tyrosinase groups in melanocytes, so that the whitening and spot-fading effects are good, and the pure oil preparation does not contain water which is easy to evaporate quickly, so that the concentration of the phenethyl resorcinol smeared on the skin is more stable, the concentration of the phenethyl resorcinol inside and outside the skin is not changed greatly, and the stimulation of the phenethyl resorcinol on the skin is reduced.
Description
Technical Field
The invention relates to the technical field of skin care products, in particular to a phenylethyl resorcinol slow-release oil agent for whitening and spot lightening.
Background
The skin care products for whitening and lightening spots in the prior art or on the market at present have two technical defects:
firstly, the existing skin care product formula only emphasizes the inhibition of the activity of three key tyrosinase groups (tyrosinase TYR, DHICA oxidase TRP-1 and dopachrome tautomerase TRP-2) which synthesize and generate melanin in melanocytes on the mechanism of whitening and spot lightening, and reduces the synthesis of melanin; various inflammatory factors and cytokines outside melanocytes are not inhibited or antagonized, and the factors can stimulate proliferation and division of melanocytes, increase and activate the concentration of tyrosinase family, prolong melanin secretion and transportation channels (cell dendrites), promote synthesis of melanin and secretion and transportation to stratum corneum, further lead the skin color to become black and deepen color spots.
Second, phenylethyl resorcinol (377 for short) is an active ingredient for whitening and spot-lightening which enters the catalogue of names of used cosmetic raw materials (INCI) after approval of related national departments in 2015, and has good whitening and spot-lightening effects due to strong inhibition on tyrosinase families in melanocytes, and more skin care products are selected. However, the prior whitening and spot-lightening skin care product containing phenylethyl resorcinol (377) is mainly cream containing a large amount of water in the formulation. When the cream is applied to the skin, the concentration of the phenylethyl resorcinol on the surface of the skin is rapidly increased due to rapid water evaporation, the diffusion speed of the phenylethyl resorcinol to the inner layer of the skin is accelerated due to overhigh concentration difference of the phenylethyl resorcinol inside and outside the skin, a capsaicin receptor TRPV1 inside the skin is further stimulated, discomfort such as skin stabbing pain, redness and the like can be caused in a short time, and the acceptance of customers is reduced. Meanwhile, in the aqueous cream formulation, the phenethyl resorcinol is easily hydrolyzed, oxidized and photodegraded due to the presence of moisture and oxygen, making it difficult to stably store the phenethyl resorcinol. According to experience and preliminary data, the product can turn yellow and degrade about half a year, and the actual shelf life and use of the product are influenced.
Disclosure of Invention
In order to solve the problems pointed out in the background art, the invention provides a phenylethyl resorcinol slow-release oil agent for whitening and lightening spots.
The technical scheme of the invention is realized as follows:
a phenethyl resorcinol slow-release oil agent for whitening and spot lightening is characterized by comprising a substrate and an anti-inflammatory composition,
the anti-inflammatory composition comprises the following components in percentage by mass: 0.5-50% of glass chicory seed oil, 0.3-3% of bisabolol, 0.3-3% of glycyrrhetinic acid stearate and 1-10% of alkanna tinctoria root extract.
Preferably, the matrix is configured as caprylic capric triglyceride.
Preferably, the composition also comprises phenylethyl resorcinol with the concentration of 0.1-1% by mass ratio.
In conclusion, the beneficial effects of the invention are as follows:
1. the anti-inflammatory composition can inhibit and antagonize the stimulation of various inflammatory factors and cytokines outside the melanocyte to the melanocyte at multiple targets, so that the whitening and spot-lightening efficiency of the product is higher, and the effect is better; meanwhile, the anti-inflammatory composition can improve skin inflammation, such as symptoms of redness, sensitivity, pruritus, redness and swelling, and the like, and achieve additional benefits;
2. the caprylic capric triglyceride matrix oil solution added with phenethyl resorcinol has strong inhibition on tyrosinase family in melanocytes, so that the whitening and spot-fading effects are good; compared with the traditional cream containing water, the pure oil does not contain water which is easy to evaporate quickly, so that the concentration of the phenylethyl resorcinol oil solution applied to the skin is more stable, the concentration difference of the phenylethyl resorcinol inside and outside the skin does not change greatly along with time, and the slow release effect on the skin is realized, so that the stimulation of the phenylethyl resorcinol to the skin is reduced.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without creative efforts.
Fig. 1 is a comparison graph of the release rate/time of phenylethyl resorcinol in the use experiment of liposome particle emulsion with submicron phenylethyl resorcinol, common emulsion with phenylethyl resorcinol, and caprylic capric triglyceride oil solution with phenylethyl resorcinol.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention is illustrated as follows:
a slow-release oil solution of phenethyl resorcinol for whitening skin and lightening spots is an oil solution taking caprylic capric triglyceride as a matrix, and comprises an anti-inflammatory composition and phenethyl resorcinol, wherein the anti-inflammatory composition is named as 'Fufujing'. The anti-inflammatory composition is used for inhibiting or antagonizing various inflammatory factors and cytokines outside melanocytes; the phenylethyl resorcinol is used for inhibiting tyrosinase in melanocytes, and in an oil solution with caprylic capric triglyceride as a matrix, because the caprylic capric triglyceride coated on the surface of the skin is not easy to evaporate, the phenylethyl resorcinol concentration on the surface of the skin is more stable, the concentration difference between the inside and the outside of the skin is not greatly changed along with time, and the slow release effect on the skin is realized, so that the irritation of the phenylethyl resorcinol on the skin is reduced.
The anti-inflammatory composition 'Yufujing' consists of the following components in percentage by mass: 0.5-50% of glass chicory seed oil, 0.3-3% of bisabolol, 0.3-3% of glycyrrhetinic acid stearate and 1-10% of alkanna tinctoria root extract. Each component of the anti-inflammatory composition inhibits or antagonizes different inflammatory factors and cytokines outside melanocytes respectively, thereby inhibiting the stimulation of the melanocytes by various inflammatory factors and cytokines in a multi-target way. The synthesis of melanin is reduced from the links of proliferation and division of melanocytes, activation of tyrosinase family, synthesis of melanin, secretion and transportation to stratum corneum and the like.
The following table: the anti-inflammatory target and the mechanism of inhibiting melanin of each component of the anti-inflammatory composition are shown.
Note: "x" indicates inhibition or antagonism and "-" indicates no inhibition or antagonism.
0.1 to 1 mass percent of phenethyl resorcinol (377 for short) is added into an oil solution agent taking caprylic capric triglyceride as a matrix. Compared with liposome emulsion added with submicron phenylethyl resorcinol, common emulsion added with phenylethyl resorcinol, and caprylic capric triglyceride oil solution added with phenylethyl resorcinol, fig. 1 is a comparison graph of release rate/time of phenylethyl resorcinol diffusing and permeating to skin in the use experiment. Fig. 1 notes: the vertical axis "release ratio" represents the phenethyl resorcinol release rate, i.e. (amount of phenethyl resorcinol released after application) ÷ (total amount of phenethyl resorcinol); the horizontal axis represents time after application.
As can be seen from fig. 1, the caprylic/capric triglyceride oil solution with added phenylethyl resorcinol has the smallest phenylethyl resorcinol release rate when being used for a longer time, and then the concentration difference of the phenylethyl resorcinol inside and outside the skin is not changed greatly, so that the slow release effect on the skin is realized, and the irritation of the phenylethyl resorcinol on the skin is reduced.
The invention is an oil solution agent with caprylic/capric triglyceride as a matrix, no moisture and oxygen exist in an oily environment, the phenethyl resorcinol is not easy to hydrolyze, oxidize and photodegrade, and becomes more stable, the storage time can reach more than 3 years, and the oil solution agent meets the cosmetic quality-keeping standard.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (3)
1. A phenethyl resorcinol slow-release oil agent for whitening and spot lightening is characterized by comprising a substrate and an anti-inflammatory composition,
the anti-inflammatory composition comprises the following components in percentage by mass: 0.5-50% of glass chicory seed oil, 0.3-3% of bisabolol, 0.3-3% of glycyrrhetinic acid stearate and 1-10% of alkanna tinctoria root extract.
2. The slow-release oil agent of phenethyl resorcinol for whitening and spot lightening as claimed in claim 1, wherein the matrix is caprylic capric triglyceride.
3. The slow-release oil agent of phenethyl resorcinol for whitening and spot-lightening according to claim 2, characterized by further comprising phenethyl resorcinol at a concentration of 0.1-1% by mass ratio.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110298197.1A CN112891237A (en) | 2021-03-19 | 2021-03-19 | Phenethyl resorcinol slow-release oil agent for whitening and spot lightening |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110298197.1A CN112891237A (en) | 2021-03-19 | 2021-03-19 | Phenethyl resorcinol slow-release oil agent for whitening and spot lightening |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112891237A true CN112891237A (en) | 2021-06-04 |
Family
ID=76106740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110298197.1A Pending CN112891237A (en) | 2021-03-19 | 2021-03-19 | Phenethyl resorcinol slow-release oil agent for whitening and spot lightening |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112891237A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107496190A (en) * | 2017-10-15 | 2017-12-22 | 广州汀兰生物科技有限公司 | A kind of whitening spot-eliminating composition and its application |
| CN110420132A (en) * | 2019-08-30 | 2019-11-08 | 西安博和医疗科技有限公司 | Whitening and skin-protecting composition and preparation method thereof |
| CN111067832A (en) * | 2020-01-08 | 2020-04-28 | 澳宝化妆品（惠州）有限公司 | Facial care product for repairing sensitive skin and resisting premature senility |
-
2021
- 2021-03-19 CN CN202110298197.1A patent/CN112891237A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107496190A (en) * | 2017-10-15 | 2017-12-22 | 广州汀兰生物科技有限公司 | A kind of whitening spot-eliminating composition and its application |
| CN110420132A (en) * | 2019-08-30 | 2019-11-08 | 西安博和医疗科技有限公司 | Whitening and skin-protecting composition and preparation method thereof |
| CN111067832A (en) * | 2020-01-08 | 2020-04-28 | 澳宝化妆品（惠州）有限公司 | Facial care product for repairing sensitive skin and resisting premature senility |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ertam et al. | Efficiency of ellagic acid and arbutin in melasma: A randomized, prospective, open‐label study | |
| EP1438015B1 (en) | Cosmetic and dermopharmaceutical compositions for skin prone to acne | |
| EP0737199B1 (en) | Method for preparing concentrated biologically active silicon compounds | |
| Tengamnuay et al. | Artocarpus lakoocha heartwood extract as a novel cosmetic ingredient: evaluation of the in vitro anti‐tyrosinase and in vivo skin whitening activities | |
| Corsini et al. | Endogenous interleukin-1α is associated with skin irritation induced by tributyltin | |
| KR20070097092A (en) | Composition and method for treating hyperpigmented skin | |
| TW201000142A (en) | Oral care product and methods of use and manufacture thereof | |
| FR2824334A1 (en) | Screening method for identifying inhibitors of lipoprotein lipase, useful in pharmaceuticals and cosmetics, particularly for treatment of fatty deposits in the skin | |
| CN110279639A (en) | A kind of aloe U.S. flesh protects Essence and preparation method thereof and application method more | |
| CN108578261A (en) | A kind of water solubility whitening composite formula and its preparation method and application | |
| CN101467950A (en) | Functional composition containing natural hot spring water for skin | |
| WO2018066704A1 (en) | Melanin inhibitor, antibacterial agent, antiallergic agent, accelerator for collagen production, and moisturizer | |
| CN112891237A (en) | Phenethyl resorcinol slow-release oil agent for whitening and spot lightening | |
| EP2413887B1 (en) | Nail-hardening cosmetic composition, use of aldehydes to harden and strengthen nails, and method for applying same | |
| Prathyusha et al. | Formulation and evaluation of polyherbal face scrubber for oily skin in gel form | |
| KR102011669B1 (en) | A cosmetic composition using antimicrobial peptide for anti-acne | |
| EP2629752B1 (en) | Cosmetic or dermatological composition including an angelica extract, and use thereof for moisturisation and radiance | |
| CN111821217A (en) | Cosmetic composition, cosmetic and preparation method thereof | |
| JP2719300B2 (en) | Melanin production inhibitor | |
| JPH06227959A (en) | Melanin formation inhibitor and skin cosmetic | |
| CN109998942A (en) | A kind of multiple-effect lightening compositions and preparation method thereof | |
| JPH0987164A (en) | Skin preparation for external use | |
| JP7320808B2 (en) | Skin topical agent | |
| FR3094637A1 (en) | Dextran sulfate in inflammatory dermatoses | |
| CN115337215B (en) | Product rich in water-soluble beta-1, 3 glucan and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210604 |
|
| RJ01 | Rejection of invention patent application after publication |